Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world
- 13.06.2023
- Epidemiology
Erschienen in:
- Verfasst von
- Megan Kruse
- Emily Nash Smyth
- Lee Bowman
- Santosh Gautam
- Claudia M. Guimaraes
- Alnecia R. Nisbett
- Maxine D. Fisher
- Zhanglin Lin Cui
- Kristin M. Sheffield
- Kevin Kalinsky
- Erschienen in
- Breast Cancer Research and Treatment | Ausgabe 1/2023
Abstract
Purpose
Cyclin Dependent Kinase 4 & 6 inhibitors (CDK4 & 6i) have transformed the management of HR+, HER2− metastatic breast cancer (MBC); however, the optimal sequence of these treatments and other systemic therapies for MBC remains unclear.
Methods
This study analyzed electronic medical records from the ConcertAI Oncology Dataset. US patients who received abemaciclib and at least one other systemic line of therapy (LOT) for HR+, HER2− MBC were eligible. Treatment sequences were grouped, and data for two pairs of groups are presented herein (N = 397): Group 1 (1L CDK4 & 6i to 2L CDK4 & 6i) vs. Group 2 (1L CDK4 & 6i to 2L non-CDK4 & 6i), and Group 3 (2L CDK4 & 6i to 3L CDK4 & 6i) vs. Group 4 (2L CDK4 & 6i to 3L non-CDK4 & 6i). Time-to-event outcomes (PFS and PFS-2) were analyzed using Kaplan–Meier method and Cox proportional hazard regression.
Results
In the total cohort of 690 patients, the most prevalent sequence was 1L CDK4 & 6i to 2L CDK4 & 6i (n = 165). For the 397 patients across Groups 1–4, sequential CDK4 & 6i demonstrated numerically longer PFS and PFS-2 versus non-sequential CDK4 & 6i. Adjusted results demonstrate that patients in Group 1 demonstrated significantly longer PFS (p = 0.05) versus Group 2.
Conclusions
Although retrospective and hypothesis-generating, these data demonstrate numerically longer outcomes in the subsequent LOT associated with sequential CDK4 & 6i treatment.
Anzeige
- Titel
- Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world
- Verfasst von
-
Megan Kruse
Emily Nash Smyth
Lee Bowman
Santosh Gautam
Claudia M. Guimaraes
Alnecia R. Nisbett
Maxine D. Fisher
Zhanglin Lin Cui
Kristin M. Sheffield
Kevin Kalinsky
- Publikationsdatum
- 13.06.2023
- Verlag
- Springer US
- Erschienen in
-
Breast Cancer Research and Treatment / Ausgabe 1/2023
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217 - DOI
- https://doi.org/10.1007/s10549-023-06993-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
